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Abstract  
Background/Aims: Visceral adiposity index (VAI) has been proposed as a marker of 
visceral adipose tissue accumulation/dysfunction. Our aim was to evaluate potential 
associations between the VAI and the 10-year cardiovascular disease (CVD) 
incidence. Methods and Results: During 2001-2002, 3042 Greek adults (1514 men; 
age: ≥ 18 years) without previous CVD were recruited into the ATTICA study, whilst 
the 10-year study follow-up was performed in 2011-2012, recording the fatal/non-
fatal CVD incidence in 2020 (1010 men) participants. The baseline VAI scores for 
these participants were calculated based on anthropometric and lipid variables, while 
VAI tertiles were extracted for further analyses. During the study follow-up a total of 
317 CVD events (15.7%) were observed. At baseline, the participants’ age and the 
prevalence of hypertension, diabetes, hypercholesterolemia and metabolic syndrome 
increased significantly across the VAI tertiles. After adjusting for multiple 
confounders, VAI exhibited a significantly independent positive association with the 
10-year CVD incidence (OR= 1.05, 95%CI: 1.01, 1.10), whereas the association of 
the body mass index (HR= 1.03, 95%CI: 0.99, 1.08), or the waist circumference 
(HR= 1.01, 95%CI: 0.99, 1.02) was less prominent. Sex-specific analysis further 
showed that VAI remained significantly predictive of CVD in men alone (HR= 1.06, 
95%CI: 1.00, 1.11) but not in women (HR= 1.06, 95%CI: 0.96, 1.10). Conclusions: 
Our findings show for the first time in a large-sample, long-term, prospective study in 
Europe that the VAI is independently associated with elevated 10-year CVD risk, 
particularly in men. This suggests that the VAI may be utilized as an additional 
indicator of long-term CVD risk for Caucasian/Mediterranean men without previous 
CVD. 
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TNF-α  Tumor necrosis factor α 
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CI  Confidence Interval 
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 1. Introduction  
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, 
representing 31% of the total global mortality in 2012 [1]. Abdominal (visceral) fat 
adiposity together with insulin resistance and metabolic syndrome (MetS) 
components (e.g. type 2 diabetes, hyperlipidemia, hypertension) are key risk factors in 
the development of CVD [2-4]. Notably, the distribution of excess adipose tissue is 
regarded as a more important CVD risk factor than obesity per se [5]. Indeed, 
although epidemiological data show that there is higher prevalence of cardiometabolic 
complications associated with increasing body mass index (BMI), there is often 
remarkable heterogeneity amongst individuals with similar BMI values [6, 7]. As 
such, data from the INTERHEART study, evaluating the impact of obesity on CVD, 
have shown that visceral adiposity contributes more than BMI to CVD risk [7]. 
Moreover, Yusuf et al. further specified that the association between visceral obesity 
and coronary heart disease (CHD) risk was significant in all 52 countries of the 
INTERHEART study [8]. 
Recently, the Visceral Adiposity Index (VAI) has been identified as a simple, 
reliable marker of visceral adiposity dysfunction that reflects cardiometabolic risk [9]. 
VAI was introduced as a sex-specific index, based on simple anthropometric 
measures [waist circumference (WC) and BMI] and common lipidemic parameters 
[triglycerides (TG), and high-density lipoprotein (HDL) cholesterol], expressing 
visceral fat function. Indeed, in 2010 Amato et al. first showed in a population of 
1498 Caucasian adults from the retrospective Alkam Metabolic Syndrome 
(AlkaMeSy) Study that increased VAI was independently associated with 
cardiovascular (2.5-fold increase) and cerebrovascular events (1.5-fold increase), 
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whilst this novel index also proved to be a better indicator for incident diabetes than 
its individual components (i.e., WC, BMI, TG, HDL) [10]. 
Importantly, VAI has been proposed as a prognostic tool of early 
cardiometabolic risk even when overt MetS manifestations are absent [11]. However, 
to date there is a paucity of long-term, prospective studies evaluating the CVD risk 
predictive power of VAI. Thus, the aim of the present work was to evaluate potential 
associations between the VAI values at the baseline/entry examination of the 
ATTICA Study and the documented 10-year CVD incidence in this cohort of 
Caucasian adults without previous CVD. 
 
2. Materials and Methods 
2.1 ATTICA Study Cohort  
The ATTICA Study is a prospective, population-based study conducted in the greater 
metropolitan area of Athens (Greece). The study baseline examination was performed 
during 2001-2002, as previously described [12]. Briefly, the study was designed to 
enrol only one participant per household through a random, multistage process based 
on the age/sex distribution of the Attica region (2001 Census). A total of 3042 
Caucasian adults [1514 men (18-87 years); 1528 women (18-89 years)] agreed to 
participate and were assessed by trained personnel, as per study protocol [12]. 
Exclusion of CVD at baseline was performed through a detailed clinical evaluation by 
the study physicians. 
 
2.2 Baseline measurements 
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The baseline study data included demographic characteristics (age; sex; years of 
education), personal/family history of hypertension, hypercholesterolemia and 
diabetes, CVD family history, as well as dietary and other lifestyle habits, such as 
smoking status (pack years) and physical activity. The dietary evaluation was based 
on a validated semi-quantitative food-frequency questionnaire, i.e. the EPIC-Greek 
questionnaire [13], which was kindly provided by the Unit of Nutrition of Athens 
Medical School. The MedDietScore was also applied to assess adherence to the 
Mediterranean diet (range 0-55; higher score values indicate better adherence) [14]. 
To assess the physical activity status of study participants the International Physical 
Activity Questionnaire was used (IPAQ), as an index of weekly energy expenditure, 
and participants not reporting any physical activities were defined as physically 
inactive [15]. Moreover, simple anthropometric indices were measured/calculated for 
all study participants, including BMI (kg/m2), WC (cm), waist to hip ratio (WHR), 
and waist to height ratio (WHtR). Resting arterial blood pressure (BP; mean of 3 
recordings) was also measured at the end of the baseline physical examination and 
participants with average BP ≥140/90 mmHg [or on antihypertensive medication(s)] 
were classified as hypertensive. Finally, blood samples were collected between 8 to 
10 a.m., after 12 hours of fasting and alcohol abstinence. Total serum cholesterol, 
HDL-cholesterol, and TG were measured using a chromatographic enzymatic method 
in a Technicon automatic analyser RA-1000 (Dade Behring, Marburg, Germany). 
Hypercholesterolemia was defined as total cholesterol levels >200 mg/dl (or use of 
lipid lowering agents). Blood glucose levels (mg/dl) were measured with a Beckman 
Glucose Analyzer (Beckman Instruments, Fullerton, CA, USA) and diabetes mellitus 
was defined according to the American Diabetes Association criteria (i.e., fasting 
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blood glucose >125 mg/dl). Furthermore, to assess circulating pro-inflammatory 
biomarkers, measurements were performed for: C-reactive protein (CRP) by particle-
enhanced immunonephelometry (N Latex; Dade-Behring Marburg GmbH, Marburg, 
Germany);  interleukin-6 (IL-6) by a high-sensitivity enzyme-linked immunosorbent 
assay (ELISA; R&D Systems Europe Ltd, Abingdon, United Kingdom); and tumor 
necrosis factor-alpha (TNF-α) by ELISA (Quantikine HS/human TNF-α, R&D 
Systems, Inc. Minneapolis, MN), following the manufacturer’s protocols. 
For the purposes of this study, according to the criteria for the clinical 
diagnosis of the MetS proposed in 2009 by the joint statement of the International 
Diabetes Federation (IDF); National Heart, Lung, and Blood Institute (NHLBI); 
American Heart Association (AHA); World Heart Federation; International 
Atherosclerosis Society; and International Association for the Study of Obesity [16], 
the study participants were also classified according to MetS presence at baseline, 
based on whether three or more of the following components were present: (i) WC 
≥102 cm for males or ≥88 cm for females (WC thresholds for abdominal obesity in 
the 2009 MetS definition recommended by the European Cardiovascular Societies for 
European populations [16]); (ii) TG ≥150 mg/dl (or on drug treatment for elevated 
TG); (iii) HDL-cholesterol <40 mg/dL for males or <50 mg/dL for females (or on 
drug treatment for reduced HDL-cholesterol); (iv) systolic BP ≥130 mm Hg or 
diastolic BP ≥85 mm Hg (or on antihypertensive drug treatment); (v) fasting blood 
glucose ≥100 mg/dL (or on antidiabetic treatment). 
 
2.3 Visceral adiposity index (VAI) assessment 
The VAI was calculated for each study participant at the baseline study 
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examination, as previously described by Amato and colleagues [9]. Briefly, using 
BMI (kg/m2), WC (cm), TG (mmol/l) and HDL (mmol/l), the proposed equations for 
calculating VAI in males and females are as follows: 
 
For the analyses of this study, VAI tertiles (<2.4; 2.4-4.5; >4.5) were also extracted 
for the study sample. 
 
2.4 Follow-up ATTICA Study examination (2011-2012) 
During 2011-12, the ATTICA Study 10-year follow-up (mean follow-up: 8.41 years) 
was performed, as previously described [17]. Of the 3042 initially enrolled 
participants, 2583 were re-evaluated for this follow-up [85% participation rate; mean 
age at baseline (years±SD): 45±14 and 46±14 years for women and men, respectively, 
with no difference to the overall study sample]. Detailed evaluation of the medical 
records of all participants (n=2583) for their 10-year CVD status was performed and 
data (with WHO-ICD coding) were collected for: (a) vital status (death from any 
cause or due to CVD); (b) development of CVD, including myocardial infarction, 
angina pectoris, other identified forms of ischemia, heart failure of different types, 
chronic arrhythmias and stroke [17]. Regarding CVD status at the follow-up, 
complete and clinically accurate data were obtained from 2020 participants. The 
scope of the present work focuses on the role of VAI as a predictor of CVD risk, thus 
herein we present our data in relation to the 10-year incidence of fatal/non-fatal CVD. 
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2.5 Bioethics 
The study was approved by the Institutional Bioethics Committee and was carried out 
in accordance to the Declaration of Helsinki (1989) of the World Medical 
Association. Prior to any study procedures, all participants were informed about the 
study protocol, and provided written signed consent. 
 
2.6 Statistical analysis 
Crude, non-fatal and fatal incidence rates of combined CVD (i.e., CHD or stroke) 
were calculated as the ratio of new cases to the number of participants in the follow-
up. Continuous variables are presented as mean values ± standard deviation (SD) and 
categorical variables as frequencies. Associations between categorical variables were 
tested using the chi-square test, while between continuous variables using Pearson r 
or Spearman’s rho coefficients for the normally and skewed variables, respectively. 
Comparisons of mean values of normally distributed variables between those study 
participants who developed a CVD event and the rest of the participants were 
performed using Student’s t-test, after controlling for equality of variances using the 
Levene’s test. Comparisons of continuous variables without normal distribution were 
performed using the non-parametric U-test proposed by Mann and Whitney. 
Continuous variables were tested for normality through P-P plots. The hazard ratios 
(HR) and the corresponding 95% confidence intervals (CI) of developing a CVD 
event during the 10-year follow-up period, according to the participants’ baseline 
characteristics were estimated using Cox proportional hazards models. Moreover, 
Hosmer-Lemeshow statistic and -2logLikelihood were calculated to evaluate model’s 
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goodness-of-fit, and Negelkerke R-square as a proxy of models discriminant power. 
The time to CVD event was recorded on an annual basis. All reported p-values are 
based on two-sided tests and the corresponding 95% CI. The Statistical Package for 
Social Sciences (SPSS) version 21 (SPSS Inc, Chicago, IL, U.S.A.) was used for all 
statistical analyses. 
3. Results 
3.1 10-year CVD incidence and baseline VAI correlations 
 The 10-year fatal or non-fatal CVD event rate was 157 cases/1000 participants 
[i.e., n=317 subjects; men: n=198 (195 cases/1000 participants); women: n=119 (118 
cases/1000 participants); p for gender difference <0.001]. VAI scores at baseline were 
positively correlated with BMI, WC, WHR, WHtR, CRP, IL-6, TNF-α, TG, total 
cholesterol, and glucose levels (rho= 0.262, 0.331, 0.280, 0.329, 0.147, 0.168, 0.136, 
0.915, 0.309, 0.227, respectively; all p-values <0.001), and inversely associated with 
HDL-cholesterol (rho= -0.395; p <0.001). Even when the analysis was stratified by 
gender these correlations remained significant for both men and women (data not 
shown).  
 
3.2 Baseline characteristics of study participants by VAI tertiles 
 Baseline characteristics of the study sample, according to the 10-year CVD 
status, are presented in Table 1. Compared to CVD-free participants, the group of 
participants who developed CVD during the 10-year follow-up consisted mainly of 
older men, heavier smokers, and had higher BMI, WC, WHR, WHtR and TG/HDL 
ratio values. Furthermore, this group also exhibited higher fasting lipid and glucose 
levels, higher BP, as well as worse Mediterranean Diet adherence (i.e., lower 
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MedDietScore) (all p-values <0.001). Participants with a CVD event during the 10-
year study follow-up had 29% higher VAI baseline values compared to those without 
(p <0.001).  
For the purposes of this study, the 2020 study participants with complete 10-
year CVD incidence data were further grouped in VAI tertiles (<2.4; 2.4-4.5; >4.5) 
based on their baseline VAI scores as presented in Table 2. Overall, the age of 
participants and the baseline prevalence of hypertension, diabetes, 
hypercholesterolemia and MetS increased significantly across VAI tertiles. Of note, 
study participants in the 1st VAI tertile (reflecting a less dysfunctional visceral adipose 
tissue profile) were younger, mostly women, lighter smokers, more physically active, 
and with lower total and central obesity, and higher Mediterranean diet adherence 
(i.e., higher mean MedDietScore: 28 out of 55) compared to those in the 3rd VAI 
tertile (highest VAI values). Furthermore, the participants in the lower VAI tertile 
also exhibited decreased baseline prevalence of various established cardiometabolic 
risk factors (i.e., hypertension, diabetes, hypercholesterolemia and MetS; all p-values 
<0.001). As expected, these participants in the 1st VAI tertile exhibited the lowest 10-
year CVD incidence.   
 
3.3 Ten-year CVD incidence and VAI  
 The aforementioned comparisons may be prone to residual confounding due to 
various potential factors; therefore, a multi-adjusted analysis was also performed, 
controlling for multiple CVD covariates. Importantly, variables being part of the VAI 
formulas (i.e., BMI, WC, TG and HDL) were not included in the models with VAI 
due to multicollinearity. Table 3 presents the results from the multi-adjusted analyses 
12 
 
 
in the context of this study, evaluating VAI and the risk of having a CVD event (fatal 
or non-fatal) within the 10-year follow-up period. Our study Full Model 1 included 
common demographic factors (age and male sex), clinical characteristics (i.e., 
hypertension, diabetes, hypercholesterolemia) and certain factors (i.e., smoking, 
physical activity, educational level, and Mediterranean diet adherence) that generally 
predict the 10-year CVD incidence. When VAI was included in the analyses, binary 
logistic regression models showed that it was independently associated with the 10-
year CVD risk. Indeed, VAI was associated with higher 10-year CVD incidence in the 
age-sex adjusted analysis (Model 2, Table 3). This association remained even after 
adjusting for smoking, physical activity educational level and the MedDietScore, as 
well as for other established CVD risk factors (i.e., hypertension, diabetes, and 
hypercholesterolemia) (Model 3, Table 3). Model 3 was further adjusted for certain 
circulating inflammatory biomarkers, i.e. CRP, IL-6 and TNF-α, to explore the 
potential mediating role of pro-inflammatory processes in the association between 
adiposity and CVD. Thus, CRP, IL-6 and TNF-α, were entered consecutively and 
separately in Model 3, as presented in Model 4, 5, and 6, respectively. According to 
these latter models, CRP, IL-6 and TNF-α appeared to similarly impact on VAI when 
entered in Model 3, since the VAI-CVD association shifted borderline towards 
significance, suggesting possible mediating effects. Overall, the presented binary 
logistic regression models showed that VAI is an index/indicator that independently 
predicts 10-year CVD risk within our study cohort. Notably, as seen in Model 3, a 
2.5-unit increase of the VAI score, which is approximately the difference in the means 
between the CVD event-free study group and the CVD group, was associated with 
13% increase of the 10-year CVD event risk. 
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Furthermore, to compare the predictive value of VAI on the 10-year CVD risk 
against more simple anthropometric and lipidemic variables/ratios (some of which are 
included in the VAI formulas), additional analyses were applied including models 
which instead of the VAI included BMI, WC, WHR, WHtR and TG/HDL-cholesterol, 
respectively. Table 4 presents the HR and 95% CI of these models, whilst the 
Hosmer-Lemeshow test was used to compare head-to-head the CVD predictive value 
of VAI against the rest of these variables. As presented in Table 4, VAI had a better 
CVD prognostic value (HR= 1.05, 95%CI: 1.01, 1.10, -2Loglikelihood= 517) than 
BMI (HR= 1.03, 95%CI: 0.99-1.08, -2Loglikelihood= 701).  In addition, VAI proved 
to be superior than all the other anthropometric indices, including WC (HR= 1.01, 
95%CI: 0.99, 1.02, -2Loglikelihood= 692), WHR (HR= 1.33, 95%CI: 0.18, 9.98, -
2Loglikelihood= 687), and WHtR (HR= 2.71, 95%CI: 0.21, 5.45, -2Loglikelihood= 
690) and the TG/HDL ratio (HR= 1.07, 95%CI: 1.01, 1.14, -2Loglikelihood= 523). 
To test how much the VAI adds to the predictive and discriminant power of the 
HellenicSCORE [18] (a tool that evaluates 10-year risk of fatal CVD events using 
age, sex, smoking, total cholesterol and blood pressure levels, according to the ESC 
SCORE project), an additive logistic model was developed. It was observed that 
inclusion of VAI on the model contained HellenicSCORE improved models' 
predictive ability by 2% (-2log Likelihood of the crude model 1106 vs. the model that 
included VAI, 1084) and the "discriminant power" from 18.5% to 20.7% (Nagelkerke 
R-square). 
Finally, taking into account that VAI is a sex-specific index, the analysis 
described in Model 3 (Table 3) was repeated separately in men and women. These 
results showed that VAI remained significantly predictive of CVD in men alone (HR= 
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1.06, 95%CI: 1.00, 1.11,) but not in women (HR= 1.06, 95%CI: 0.96, 1.10). 
Furthermore, the VAI had better predictive ability against 10-year CVD incidence 
when examined in men alone (HR= 1.06, 95%CI: 1.00, 1.11,-2Loglikelihood= 128) 
compared to the whole study sample (HR= 1.05, 95%CI: 1.01, 1.10, -
2Loglikelihood= 517).  
 
4. Discussion 
 Our study presents novel data from a large cohort of prospectively followed 
Caucasian (Mediterranean/Greek) adults without previous CVD, showing that higher 
VAI scores (indicating accumulated dysfunctional visceral adipose tissue [9]) exhibit 
a significant and independent association with 10-year CVD incidence, particularly in 
men. Interestingly, this positive association remained even after taking into account a 
wide range of potential confounders, including lifestyle factors and 
clinical/biochemical variables. Indeed, in our fully adjusted model only VAI was a 
significant indicator of the 10-year CVD risk, independently of other established 
CVD factors. Thus, it could be hypothesized that because VAI takes into account both 
anthropometric (BMI and WC) and metabolic/lipidemic (TG and HDL) variables of 
obesity (particularly central obesity), it may reflect more directly the array of potential 
pro-atherogenic processes that in the long-term result in higher CVD risk (e.g. 
visceral and ectopic fat deposition, dysregulated adipokine production, and increased 
adipose tissue lipolysis and free fatty acid efflux) [19-21].  
The mechanisms by which VAI may be associated with CVD risk are not fully 
understood. Of note, when inflammation (as expressed by circulating CRP, IL-6 and 
TNF-a) was tested in this study in a mediation analysis, as a possible explanatory 
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factor of the association between VAI and 10-year CVD risk, the effect of VAI 
baseline values on 10-year CVD incidence remained significant. This could be 
potentially attributed to a positive association of VAI with higher long-term CVD risk 
through early pro-inflammatory mechanisms related to dysfunctional visceral 
adiposity (e.g. altered adipokine profile, including amplified secretion of pro-
inflammatory adipokines and cytokines, such as IL-6 and TNF-a), which are not 
always directly reflected in the clinical evaluation of CVD risk [10].  
Additionally, sex-specific analysis in our study revealed a positive association 
of VAI on CVD risk in men, but not in women. This could be attributed to the fact 
that men - in general - as well as in our study, had greater BMI, higher WC and lower 
HDL levels. Considering that men are more susceptible to visceral adiposity, this 
could also suggest greater visceral adipose tissue dysfunction (e.g. greater changes in 
expression/secretion of multiple adipokines such as visfatin, resistin, leptin, omentin, 
and adiponectin). Thus, VAI, as an empirical mathematical model/index of adipose 
distribution and function that indirectly expresses cardio-metabolic risk [9, 10], 
appears to have higher accuracy in linking visceral obesity dysfunction and CVD risk 
in men compared to women. Nevertheless, VAI importance in predicting future CVD 
candidates should be considered irrespective of individuals' gender, since visceral 
adiposity has shown its crucial role in the development and progression of 
atherosclerotic disease in both men and women. 
Importantly, our findings indicate that the predictive effect of VAI for the 10-
year CVD incidence in this study cohort was better when compared to typically used 
anthropometric and lipidemic variables, i.e. BMI, WC, WHR, WHtR and TG/HDL 
ratio. This is significant also for the clinical practice, since it suggests that the 
16 
 
 
calculation of VAI based on the simple measurements of BMI, WC, TG and HDL-
cholesterol offers a stronger CVD indicator compared to its individual components 
and to other simpler ratios (e.g. WHR, WHtR, TG/HDL ratio).  
Over the last few decades there has been compelling evidence showing that 
adipose tissue acts as an endocrine organ with pleiotropic effects, due to the dynamic 
secretory function of adipocytes and resident macrophages [22]. These effects may 
lead to a chronic, low-grade pro-inflammatory state in obesity (particularly in 
visceral/central/android obesity) that is further associated with insulin resistance and 
CVD [22]. Indeed, sustained weight increase and adipose tissue accumulation induces 
significant changes inside the various fat depots, resulting in dysregulated function 
with increased lipolysis, insulin resistance and altered adipokine production (e.g., 
increased production of pro-inflammatory adipokines, such as leptin, and cytokines 
such as TNF-α and IL-6; and decreased production of anti-inflammatory adipokines, 
such as adiponectin and omentin) [22]. These changes are considered responsible for 
the overall adipose tissue dysfunction, playing a vital role in the obesity-related 
cardiometabolic sequelae [22-24]. Visceral adiposity appears to be a critical factor in 
the underlying pathophysiological mechanisms [6], whilst it is also hypothesized that 
subcutaneous fat has a limited capacity to safely increase its mass [25]. As such, 
emphasis has been placed in identifying simple indices which can be reliably applied 
in everyday clinical practice as surrogate markers of visceral adiposity and as 
indicators of increased cardiometabolic risk. In 2010 Amato et al. proposed VAI as a 
novel index with such attributes in the context of the retrospective AlkaMeSy study 
[9]. In the 1498 Caucasian adults of this study, VAI was shown to correlate with 
visceral adipose tissue, whilst exhibited a strong positive association with 
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cardiovascular events (OR: 2.45, 95% CI: 1.52-3.95) and an inverse association with 
insulin sensitivity [9]. Moreover, ROC analysis in this study proved VAI to have 
greater sensitivity and specificity than its individual components regarding 
cardiovascular events, although the cross-sectional nature of the study did not allow 
exploring causal inferences between VAI and CVD [9]. Since 2010, the VAI has been 
studied in various cohorts from general/healthy populations and in specific patient 
groups at increased cardiometabolic risk (e.g., in obese patients or in women with 
polycystic ovary syndrome, PCOS), with particular focus on the prediction of type 2 
diabetes [26, 27]. However, so far there are limited data from prospective studies 
exploring VAI as an indicator of long-term CVD risk. It should be also highlighted 
that, the VAI was modeled and validated on a Caucasian (Italian/Mediterranean) 
population of adults from the city of Alcamo in Western Sicily, whereas currently 
existing data on the long-term association between VAI and CVD are mostly from 
population-based studies conducted in Asia and South America [28, 29]. Indeed, a 9-
year follow-up in the context of the Tehran lipid and glucose study demonstrated that 
the VAI was associated with multivariate-adjusted, increased risk of incident CVD 
among women [28]. However, the magnitude of risk conferred by VAI in this study 
was not significantly higher than those conferred by BMI, WHR or WHtR [28]. 
Additionally, data from a long-term study in Buenos Aires (Argentina) showed that 
VAI was not able to recognize subjects at high CVD risk compared to the TG/HDL 
ratio [29]. These results are not in accord with the present findings of the ATTICA 
study, potentially due to significant differences in the ethnicity and in the age range of 
the studied cohorts [28, 29], especially since as aforementioned VAI is modeled based 
on a cohort of Caucasian adults [Caucasian (Italian/Mediterranean) men and women 
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aged between 19 and 83 years) [9, 30, 31]. Hence, the application of VAI has not 
been validated in non-Caucasian populations (e.g. the study in Tehran studied a 
population of Persian ancestry) [28], and in adolescents aged <16 years (e.g. the study 
in Buenos Aires studied a population aged ≥15 years) [29].  
Compared to available data, the significance of our findings is strengthened by 
the characteristics of our study design and population, i.e., prospective, long-term 
design, large sample size, Caucasian/Mediterranean population, and adjustment for 
multiple anthropometric and clinical parameters. In addition, our data originate from a 
reliable, prospective follow-up process in a well-characterized population-based 
sample in which CVD and its risk factors have been assessed with standardized 
measures/procedures both at baseline and during the follow-up. As such, the ATTICA 
study extends previous research on the application of VAI, indicating that this 
relatively simple index may represent a useful predictive marker for men from the 
general population in whom CVD risk classification based on simple/single variables, 
such as BMI, is particularly sub-optimal. Indeed, in the fully adjusted analyses, 
accounting for age, gender, clinical, behavioral, and pro-inflammatory variables, the 
HR (95% CIs) for 10-year CVD incidence was 1.05 (1.01, 1.10) per 1 unit increase in 
the baseline VAI score, while including separately the rest of the anthropometric 
indices (BMI, WC, WHR, WHtR) had no better predictive effect. This is also 
significant for epidemiological research studies, since additional reliable indices 
associated to visceral adiposity (android/central obesity) are still required in the effort 
to predict more accurately the obesity-related long-term cardiometabolic risk without 
the need for visceral fat assessments by imaging techniques (i.e., CT and MRI). 
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4.1 Limitations 
 Despite the aforementioned strengths, certain limitations of the present study 
should be also acknowledged. Thus, it must be noted that the baseline study 
examination was performed once and may be susceptible to measurement error. 
However, the applied methodology within our study protocol was similar to those of 
other prospective epidemiological studies in Europe and the US, and therefore our 
results can be considered reliable and comparable. Moreover, taking into 
consideration that the number of fatal events was too small [17], we decided to 
present the analyses on VAI and 10-year CVD fatal and not-fatal incidence combined. 
 
4.2 Conclusion  
 In conclusion, this study offers novel evidence revealing an independent 
positive association between the VAI and 10-year CVD incidence in men from a 
cohort of Caucasian adults without previous CVD. Thus, it may be suggested that this 
index, which reflects visceral adipose tissue accumulation/dysfunction, could be also 
applied as a relatively simple tool for long-term CVD risk assessment, at least in 
healthy or apparently healthy men of Caucasian/Mediterranean origin. Additional 
research is clearly required to further explore these findings in even larger cohorts, in 
specific patient populations (e.g. in non-alcoholic liver disease or PCOS) and in other 
ethnic groups.  
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Continuous variables are presented as mean values ± standard deviation and 
categorical variables as frequencies. P values for the comparisons between CVD 
event and event-free group derived using the t-test, while for the comparisons of 
categorical variables using the chi-square test. VAI: Visceral adiposity index; 
MedDietScore: score evaluating the adherence to the Mediterranean diet (higher score 
values indicate better adherence) 
Table 1. Demographic, behavioral, lifestyle and clinical characteristics of the ATTICA Study participants 
at baseline and at the 10-year follow-up by cardiovascular disease (CVD) status (n=2020). 
       
Baseline 
n = 2020 
CVD status at 10-year follow-up P 
CVD event free 
n=1703 
CVD events 
n= 317 
Age (years, range 18-89) 45 ± 14 43 ± 13 58 ± 13 <0.001 
Gender, %male 50.24 47.97 62.46 <0.001 
Smoking (pack years)  496 ± 501 441 ± 425 767 ± 705 <0.001 
Smoking at baseline or before, % 43 55 57 0.46 
Physical Activity, % physically active 41 40 41 0.95 
Body Mass Index (kg/m2) 26 ± 5 26 ± 5 28 ± 5 <0.001 
Waist circumference (cm) 90 ± 15 89 ± 15 97 ± 14 <0.001 
Waist to hip ratio 0.86 ± 0.1 0.85 ± 0.11 0.92 ± 0.11 <0.001 
Waist to height ratio 0.53 ± 0.08 0.52 ± 0.08 0.57 ± 0.07 <0.001 
Triglycerides to HDL-cholesterol ratio 2.79 ± 2.89 2.62 ± 2.33 4.32 ± 6.02 <0.001 
Obesity, %yes 18 20 30 <0.001 
Hypertension, %yes 30 28 51 <0.001 
Diabetes Mellitus, %yes 7  5 22 <0.001 
Hypercholesterolemia, %yes 39 40 57 <0.001 
MedDietScore (range 0-55) 26 ± 7 26 ± 6 23 ± 7 <0.001 
Metabolic syndrome, %yes 20 18 41  <0.001 
C-reactive protein (mg/L) 1.93 ± 2.4 0.99±0.9 1.42 ±1.15 <0.001 
Interleukin-6 (ng/mL) 1.46 ± 0.55 1.43± 0.55 1.65 ± 0.51 <0.001 
Tumor necrosis factor-α (pg/mL) 6.21 ± 4.90 6.00 ± 4.70 8.33 ± 5.47 <0.001 
VAI  4.4 ± 5 4.1 ± 3 6.6 ± 9 <0.001 
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Continuous variables are presented as mean values ± standard deviation and 
categorical variables as frequencies. P values for the comparisons between the 1st and 
the 3rd VAI tertile groups derived using the t-test, while for comparisons of 
categorical variables using the chi-square test. MedDietScore: score evaluating the 
adherence to the Mediterranean diet (higher score values indicate better adherence).
Table 2. Cardiovascular disease (CVD) events during the 10-year ATTICA Study follow-up, as well as  
participants' baseline characteristics (n=2020) grouped by tertiles of the Visceral Adipose Index (VAI tertiles: 
<2.4; 2.4-4.5; >4.5). 
 VAI tertiles at baseline  
 1st tertile 2nd tertile 3rd tertile P 
CVD event during 10-yr follow-up, %yes 8 12 24 <0.001 
Baseline characteristics     
Age (years) 19 ± 13 45 ± 14 50 ± 13 <0.001 
Gender, %male  42 45 58 <0.001 
Smoking (pack years) 362 ± 385  422 ± 420 617 ± 534 <0.001 
Physical Activity, % physically active 48 43 33 <0.001 
Body Mass Index (kg/m2) 24 ± 3.6 26 ± 4.5 28 ± 4.6 <0.001 
Waist circumference (cm) 82 ± 13 90 ± 14 98 ± 14 <0.001 
Waist to hip ratio 0.81 ± 0.10 0.86 ± 0.11 0.91 ± 0.12  <0.001 
Waist to height ratio 0.48 ± 0.07 0.53 ± 0.08 0.58 ± 0.08 <0.001 
Triglycerides to HDL-cholesterol ratio 1.12 ± 0.34 2.12 ± 5.06 5.06 ± 4.05 <0.001 
Education (years of school) 13 ± 3.4 12 ± 3.8 11 ± 3.9 <0.001 
Hypertension, %yes 21 32 43 <0.001 
Diabetes mellitus, %yes 2 4 13 <0.001 
Hypercholesterolemia, %yes 22 45 64 <0.001 
MedDietScore (range 0-55) 28 ± 7 26 ± 7  24 ± 6 <0.001 
Metabolic Syndrome, %yes 3 14 55 <0.001 
C-reactive protein (mg/L) 1.36 ± 2.05 2.03 ± 2.53 2.65 ± 2.6 <0.001 
Interleukin-6 (ng/mL) 1.35 ± 0.39 1.47 ± 0.40 1.6 ± 0.43 <0.001 
Tumor necrosis factor-α (pg/mL) 5.44 ± 3.81 6.41± 4.75 7.22 ± 3.63 <0.001 
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Table 3. Results from the Cox proportional hazard models applied to evaluate the 10-year risk of having a 
cardiovascular event (outcome) according to the baseline Visceral Adipose Index (VAI) values. 
All participants  Hazard Ratios (HR)*, 95% Confidence Intervals 
 Full Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
Age (per 1 year) 1.06 
(1.04-1.08) 
1.08  
(1.07-1.10) 
1.06  
(1.04-1.09) 
1.06  
(1.04-1.09) 
1.05  
(1.03-1.08) 
1.06  
(1.03-1.09) 
Men vs. Women 1.66 
(1.06-2.61) 
2.03  
(1.47-2.81) 
2.29  
(1.32-3.98) 
2.07  
(1.17-3.67) 
1.99  
(1.14-3.50) 
1.94  
(1.01-3.76) 
VAI (per 1 unit) - 1.06  
(1.02-1.09)‡ 
1.05  
(1.01-1.10)‡ 
1.04  
(1.00-1.09)‡ 
1.04  
(1.00-1.09)‡ 
1.05  
(1.00-1.11)‡ 
Smokers vs. non 
smokers 
1.00 
(1.00-1.01) 
- 1.00  
(1.00-1.01) 
1.00  
(1.00-1.01) 
1.00  
(1.00-1.05) 
1.00  
(1.00-1.01) 
Physically activity 
vs. inactive 
0.74 
(0.49-1.11) 
- 0.82  
(0.51-1.32) 
0.87  
(0.52-1.43) 
0.87  
(0.53- 1.43) 
0.63  
(0.35-1.13) 
Education (years of 
school) 
0.98 
(0.93-1.04) 
- 0.98  
(0.93-1.05) 
0.97  
(0.91-1.03) 
0.97  
(0.91-1.04) 
0.95  
(0.88-1.02) 
MedDietScore 
(range 0-55) 
0.95 
(0.92-0.99) 
- 0.96  
(0.92-1.01) 
0.95  
(0.91-1.00) 
0.95  
(0.91-0.99) 
0.95  
(0.91-1.00) 
Hypertension (y/n) 1.06 
(0.71-1.60) 
- 1.22  
(0.77-1.94) 
1.44  
(0.89-2.32) 
1.43  
(0.88-2.31) 
1.23  
(0.71-2.14) 
Diabetes Mellitus 
(y/n) 
2.39 
(1.33-4.29) 
- 2.35  
(1.18-4.70) 
2.13  
(1.02-4.43) 
2.23  
(1.08-4.62) 
2.21  
(0.91-5.39) 
Hypercholesterolemi
a (y/n) 
1.33 
(0.90-1.97) 
- 1.43  
(0.90-2.28) 
1.32  
(0.82-2.14) 
1.32  
(0.82-2.12) 
1.67  
(0.97-2.88) 
C-reactive protein 
(mg/L) 
- - - 1.12  
(1.03-1.21) 
- - 
Interleukin-6 
(ng/mL) 
 - - - - 1.62  
(0.92-2.86) 
- 
Tumor necrosis 
factor-α (pg/mL) 
           - - - - - 1.10  
(1.01-1.20) 
* Hazard Ratios derived from semi-parametric Cox proportional hazards models. ‡ p <0.05.  
MedDietScore: score evaluating the adherence to the Mediterranean diet (higher score values indicate better 
adherence).  Smoking was analyzed as a continuous variable through pack years. 
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Table 4.  Results from the additive Cox proportional hazards models developed to evaluate the predictive role of 
VAI on the risk of 10-year cardiovascular disease events (outcome) compared to other anthropometric indices 
such as  the body mass index (BMI), waist circumference, waist to hip ratio, waist to height ratio and 
triglycerides to HDL-cholesterol ratio. 
 Hazard 
Ratios (HR)2 
95% Confidence 
Intervals 
Hosmer and 
Lemeshow 
Goodness of fit test3 
Full Model1 - - 704.29 
Full Model1+ VAI 1.05 (1.01-1.10) 516.72 
Full Model1 + BMI 1.03 (0.99-1.08) 700.79 
Full Model1+ waist circumference 1.01 (0.99-1.02) 691.80 
Full Model1 + waist to hip ratio 1.33  (0.18-9.98) 687.37 
Full Model1 + waist to height ratio 2.71 (0.21-5.45) 690.42 
Full Model1 +  triglycerides to HDL-cholesterol ratio 1.07 (1.01-1.14) 526.94 
1adjusted for age, sex, smoking (pack years), physical activity (active/inactive), education (years of school), 
MedDietScore, history of hypertension, diabetes mellitus, hypercholesterolemia 
2Hazard Ratios derived from semiparametric Cox proportional hazards models.  
3The Hosmer–Lemeshow statistical test was used for goodness of fit for the logistic regression models. 
